Co-diagnostics, inc. reports first quarter 2024 financial results

Salt lake city , may 9, 2024 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) ("co-dx," or the "company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended march 31, 2024. first quarter 2024 financial results: revenue of $0.5 million, down from $0.6 million during the prior year.
CODX Ratings Summary
CODX Quant Ranking